Loading blog post…
A complete guide to bakuchiol in skincare — its origin from Psoralea corylifolia seeds, the functional retinol analog claim and what it actually means (retinol-like gene expression without RAR binding), the pivotal Dhaliwal 2019 split-face RCT against 0.5% retinol, why bakuchiol is tolerated by patients who cannot tolerate retinol, its anti-inflammatory and antioxidant properties that distinguish it from retinol, the pregnancy safety profile, and honest positioning for who should use bakuchiol vs retinol vs tretinoin.
· By MedSpot Editorial · 5 min read
Bakuchiol is the most clinically validated "natural retinol alternative" — a meroterpene with genuinely retinol-like effects on skin gene expression and observable clinical outcomes, without retinoid receptor binding. Here is the complete evidence-based guide to what it does and does not do.
Bakuchiol is a meroterpene phenol — a hybrid structure combining terpenoid and phenylpropanoid components — extracted from the seeds of Psoralea corylifolia (Babchi plant), used for centuries in Ayurvedic and traditional Chinese medicine for skin and vitiligo treatment.
The compound was identified as having retinol-like biological effects on skin in the early 2000s and entered the prestige skincare market as a "plant retinol" or "natural retinol." The marketing significantly preceded the rigorous clinical evidence, which arrived with the 2019 Dhaliwal trial.
Bakuchiol is not a retinoid — it has no structural similarity to retinol, retinal, or retinoic acid. It does not bind retinoic acid receptors (RARα, RARβ, RARγ) or retinoid X receptors.
What it does: In vitro and in vivo studies show bakuchiol upregulates many of the same genes as retinol:
These overlapping transcriptional effects on skin cells are why bakuchiol is called a "functional analog" — it produces retinol-like outcomes through an independent mechanism.
Proposed mechanism: Bakuchiol may activate PPAR (peroxisome proliferator-activated receptor) pathways and other nuclear receptor systems, and has antioxidant activity that reduces the oxidative signaling driving photoaging. The precise mechanism is not fully elucidated.
Dhaliwal S, Rybak I, Ellis SR, Notay M, Trivedi M, Burney W, Sivamani RK. (2019). Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. British Journal of Dermatology, 180(2), 289–296.
Design: Double-blind split-face RCT. 44 participants applied bakuchiol 0.5% twice daily to one side and retinol 0.5% once daily to the other side for 12 weeks.
Results:
Interpretation: Bakuchiol 0.5% b.i.d. performs equivalently to retinol 0.5% o.d. for photoaging endpoints, with a substantially better tolerability profile.
Limitation: The comparison is retinol, not tretinoin — the gold standard. Bakuchiol vs. tretinoin RCT data does not exist. The study is 12 weeks — longer-term comparative data is lacking. Single study; larger replication trials are needed.
Retinol irritation (retinization) results from:
Bakuchiol produces none of these mechanisms because it does not bind RARs:
This makes bakuchiol genuinely different from retinol in tolerability — not simply "gentler retinol" marketing but a mechanistically distinct and non-irritating profile.
Unlike retinol, bakuchiol has:
These properties make bakuchiol appropriate for inflammatory or reactive skin conditions where retinol would be contraindicated.
Retinoids (retinol, tretinoin, all forms) are contraindicated in pregnancy due to teratogenicity risk. Bakuchiol is not a retinoid — it does not bind retinoid receptors and has no teratogenicity concern from the mechanism standpoint.
The practical reality: Definitive teratogenicity studies for bakuchiol specifically do not exist (as is true for many cosmetic ingredients). Most dermatologists consider topical bakuchiol likely safe in pregnancy given its non-retinoid mechanism, though the evidence is absence of concern rather than positive safety confirmation. Contrast this with retinoids, where the evidence for harm is strong.
Bakuchiol is increasingly positioned as the retinoid substitute during pregnancy — a reasonable position given the mechanism difference, though pregnant patients should consult their OB.
Retinol intolerance: Patients who have tried retinol at low concentrations (0.025–0.05%) and experienced significant irritation despite slow escalation — bakuchiol provides comparable anti-aging benefit without the irritation mechanism.
Pregnancy or breastfeeding: Retinoids are contraindicated; bakuchiol offers a functional alternative during these periods.
Sensitive or reactive skin: Conditions like rosacea, active eczema, or compromised barrier that preclude retinoid use. Bakuchiol's anti-inflammatory profile actively benefits these patients.
Twice-daily retinoid benefit: Retinol and tretinoin are used once daily (PM only) due to photosensitivity. Bakuchiol can be used twice daily (AM and PM) — higher total daily exposure than retinol protocols allow.
Active moderate-to-severe acne: Tretinoin and adapalene have strong evidence for acne; bakuchiol does not. For acne as the primary indication, prescription retinoids are superior.
Significant photoaging with access to tretinoin: The evidence for tretinoin in photoaging is decades deeper than bakuchiol. Patients who tolerate tretinoin and have significant photoaging goals should use tretinoin.
Cost constraints: Bakuchiol products are often premium-priced; retinol at equivalent doses is significantly less expensive.
Concentration: 0.5% is the evidence-supported concentration. Many products use 0.1–0.3% — likely subtherapeutic for the Dhaliwal result to apply.
Frequency: Can be used morning and evening (unique advantage over retinol). AM use requires SPF — though bakuchiol does not cause photosensitization, daily SPF is standard for any anti-aging routine.
Layering: Compatible with most actives. Niacinamide, hyaluronic acid, and vitamin C can all be combined without conflict. No pH restrictions.
Looking for an anti-aging skincare consultation? Browse med spa providers on MedSpot →